ABBV(AbbVie/アッヴィ)
事業内容
医薬品
セクター
ヘルスケア(Health Care)
IRサイト
https://investors.abbvie.com/
現在の株価チャート
最新決算結果(2023Q4)
■EPS $2.79(予想) vs $2.79(-22.5%)
■売上高 $14.03B(予想) vs $14.30B(-5.4%)
・Humira $3.3B(-40.8%)
・Skyrizi $2.39(+51.9%)
・Rinvoq $1.26B(+62.9%)
・Imbruvica $903M(-19%)
・Venclexta $589M(+14.3%)
[FY23]
・EPS $11.13(予想) vs $11.11(-19.32%)
・売上高 $54.05B(予想) vs $54.32B(-6.4%)
■ガイダンス
[FY24]
・EPS $11.26(予想) vs $11.05 ~ $11.25
https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2023-financial
過去の決算結果
R | Q | EPS | Revenue | Guidance | |||||
est | act | est | act | EPS | Revenue | ||||
est | act | est | act | ||||||
〇 | 23Q3 | 2.70 | 2.95 | 12.92B | 13.93B | 10.42 | 11.21 | ||
〇 | 23Q2 | 2.80 | 2.91 | 13.52B | 13.87B | 10.85 | 11.00 | ||
× | 23Q1 | 2.46 | 2.46 | 12.17B | 12.23B | 10.94 | 10.92 | ||
× | 22Q4 | 3.56 | 3.60 | 15.31B | 15.12B | 11.65 | 10.90 | ||
× | 22Q3 | 3.57 | 3.66 | 14.91B | 14.81B | 13.86 | 13.86 | ||
× | 22Q2 | 3.31 | 3.37 | 14.64B | 14.58B | 13.91 | 13.88 | ||
× | 22Q1 | 3.14 | 3.16 | 13.61B | 13.54B | 14.11 | 14.02 | ||
× | 21Q4 | 3.29 | 3.31 |
14.97B | 14.89B | 13.99 | 14.10 | ||
〇 | 21Q3 | 3.22 | 3.33 | 14.32B | 14.34B | 12.6 | 12.65 |
主要指標
医薬品別売上高推移
一株当たりの業績
2019 | 2020 | 2021 | 2022 | 2023 | |
■DPS(配当金) | 4.39 | 4.84 | 5.31 | 5.71 | 5.99 |
■EPS(利益) | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 |
■CFPS(キャッシュフロー) | 8.98 | 10.51 | 12.82 | 14.03 | 12.88 |
■SPS(売上高) | 22.42 | 27.38 | 31.62 | 32.65 | 30.64 |